Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of ravulizumab for thrombotic microangiopathy after hematopoietic stem cell transplantation
MOH_2021-08-02_010186Phase 3Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jul 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in thrombotic microangiopathies (TMA) comparing Ravulizumab plus best supportive care with Placebo plus best supportive care (2 arms). Started Jul 2021; status: completed.
02
Drugs
ravulizumab
03
Conditions
thrombotic microangiopathies (TMA)
Beyond the preview
Go deeper on MOH_2021-08-02_010186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-08-02_010186.